Disc Medicine's CEO reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program
John Quisel describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light. Plus, learnings about clinical endpoints from the company's P2 experience, and highlights on two hepcidin programs.